pH-Controlled assembly of polyelectrolyte layers on silica nanoparticles in concentrated suspension

Hypothesis: Preparation of suspensions of nanoparticles (>1 wt%) coated with a polyelectrolyte multilayers is a challenging task because of the risk of flocculation when a polyelectrolyte is added to a suspension of oppositely charged nanoparticles. This situation can be avoided if the charge density of the polymers and particles is controlled during mixing so as to separate mixing and adsorption events. Experiments: The cationic polyethylenimine (PEI) and the anionic carboxymethylcellulose (CMC) were used as weak polyelectrolytes. Polyelectrolyte multilayers build-up was conducted by reducing the charge of one of the components during the addition of the next component. Charge density was controlled by tuning pH. Analysis of the suspension of coated nanoparticles was done by means of dynamic light scattering, electrophoresis and small angle x-ray scattering measurements, while quartz crystal microbalance was used to study the build-up process on flat silica surfaces. Findings: Charge density, controlled through pH, can be used as a tool to avoid flocculation during layer-by-layer deposition of polyelectrolytes on 20 nm silica particles at high concentration (∼40 wt%). When added to silica at pH 3, PEI did not induce flocculation. Adsorption was triggered by raising the pH to 11, pH at which CMC could be added. The pH was then lowered to 3. The process was repeated, and up to five polyelectrolyte layers were deposited on concentrated silica nanoparticles while inducing minimal aggregation

Exercise prescription when there is no exercise test: the talk test

The Talk Test is a subjective measure of exercise intensity which, like RPE, has come to be accepted as an alternative to objective measures (%HRR, %VO2max) for exercise evaluation and prescription. This paper reviews the history and indications for using the Talk Test as a tool for both exercise evaluation and exercise prescription. The Talk Test, in one form or the other, has a long history, dating from at least 1937. It appears to be robust relative to the method of provoking speech and to the exercise mode. In the most widely used version, the subject recites a standard paragraph of 30-100 words, and responds to the question ‘Can you speak comfortably?’ With answers of ‘Yes’ (POSITIVE), ‘Yes, but…’ (EQUIVOCAL), and ‘No” (NEGATIVE), the Talk Test appears to be able to identify exercise intensities closely associated with the ventilatory (VT) and respiratory compensation (RCT) thresholds, and to bracket subjects into %HRR intensities closely associated with the accepted exercise/training intensity guidelines, without the need for performing a maximal exercise test. The Talk Test appears to work well in a range of populations from college students, healthy adults, elite athletes to patients with chronic diseases. It also seems to be a valid and reliable marker of the presence of exertional ischemia. In a variety of populations, the Talk Test appears capable of being translated into absolute exercise training intensities, on the basis of a commonsense step down sequence. The Talk Test appears to work by allowing detection of when the suppression of breathing frequency, which is necessary for speech, begins to lead to CO2 trapping, which interferes with breathing comfort. Its response to disrupting stimuli such as stochastic exercise, exercise training and blood donation follow predictable patterns. Guiding exercise intensity using the Talk Test instead of %HRR provides comparable responses during exercise training, without the need for an anchoring maximal exercise test. In summary, the Talk Test seems to offer a considerable promise as a means of exercise evaluation and prescription, in a wide variety of exercising individuals, without the need for a preliminary exercise test

Exercise prescription when there is no exercise test: the talk test

The Talk Test is a subjective measure of exercise intensity which, like RPE, has come to be accepted as an alternative to objective measures (%HRR, %VO2max) for exercise evaluation and prescription. This paper reviews the history and indications for using the Talk Test as a tool for both exercise evaluation and exercise prescription. The Talk Test, in one form or the other, has a long history, dating from at least 1937. It appears to be robust relative to the method of provoking speech and to the exercise mode. In the most widely used version, the subject recites a standard paragraph of 30-100 words, and responds to the question ‘Can you speak comfortably?’ With answers of ‘Yes’ (POSITIVE), ‘Yes, but…’ (EQUIVOCAL), and ‘No” (NEGATIVE), the Talk Test appears to be able to identify exercise intensities closely associated with the ventilatory (VT) and respiratory compensation (RCT) thresholds, and to bracket subjects into %HRR intensities closely associated with the accepted exercise/training intensity guidelines, without the need for performing a maximal exercise test. The Talk Test appears to work well in a range of populations from college students, healthy adults, elite athletes to patients with chronic diseases. It also seems to be a valid and reliable marker of the presence of exertional ischemia. In a variety of populations, the Talk Test appears capable of being translated into absolute exercise training intensities, on the basis of a commonsense step down sequence. The Talk Test appears to work by allowing detection of when the suppression of breathing frequency, which is necessary for speech, begins to lead to CO2 trapping, which interferes with breathing comfort. Its response to disrupting stimuli such as stochastic exercise, exercise training and blood donation follow predictable patterns. Guiding exercise intensity using the Talk Test instead of %HRR provides comparable responses during exercise training, without the need for an anchoring maximal exercise test. In summary, the Talk Test seems to offer a considerable promise as a means of exercise evaluation and prescription, in a wide variety of exercising individuals, without the need for a preliminary exercise test

Do Surgical Trials Meet the Scientific Standards for Clinical Trials?

Unlike medications, the dissemination of surgical procedures into practice is not regulated. Before marketing, pharmaceutical products are required to be shown safe and efficacious in comparative clinical trials that use bias-reducing strategies designed to reduce the distortion of estimates of treatment effect by predispositions toward the investigational intervention or control. Unless an investigational device is involved, the corresponding process for surgical innovations is usually unregulated and therefore may not be based on adequate evidence. Given these differences, we sought to evaluate the state of clinical research on invasive procedures. We conducted a systematic review of publications from 1999 through 2008, which reported the results of studies evaluating the effects of invasive therapeutic procedures, focusing on trials that appeared to influence practice. Our objective was to determine what proportion of studies evaluating surgical procedures use a comparative clinical trial design and methods to control bias. This article reports our results and raises concerns about the methodologic, and therefore the ethical, quality of clinical research used to justify the implementation of surgical procedures into practice

Evaluation of single and double-locus real-time PCR assays for methicillin-resistant Staphylococcus aureus (MRSA) surveillance

<p>Abstract</p> <p>Background</p> <p>Methicillin-resistant <it>Staphylococcus aureus </it>(MRSA) is a human pathogen, representing an infection control challenge. Conventional MRSA screening takes up to three days, therefore development of rapid detection is essential. Real time-PCR (rt-PCR) is the fastest method fulfilling this task. All currently published or commercially available rt-PCR MRSA assays relay on single or double-locus detection. Double-locus assays are based on simultaneous detection of <it>mecA </it>gene and a <it>S. aureus</it>-specific gene. Such assays cannot be applied on clinical samples, which often contain both coagulase-negative staphylococci (CoNS) and <it>S. aureus</it>, either of which can carry <it>mecA</it>. Single-locus assays are based on detection of the staphylococcal cassette chromosome <it>mec </it>(SCC<it>mec</it>) element and the <it>S. aureus</it>-specific <it>orfX </it>gene, assuming that it is equivalent to <it>mecA </it>detection.</p> <p>Findings</p> <p>Parallel evaluation of several published single and double-locus rt-PCR MRSA assays of 150 pure culture strains, followed by analysis of 460 swab-derived clinical samples which included standard identification, susceptibility testing, followed by PCR detection of staphylococcal suspected isolates and in-PCR mixed bacterial populations analysis indicated the following findings.</p> <p>Pure cultures analysis indicated that one of the single-locus assay had very high prevalence of false positives (Positive predictive value = 77.8%) and was excluded from further analysis. Analysis of 460 swab-derived samples indicated that the second single-locus assay misidentified 16 out of 219 MRSA's and 13 out of 90 methicillin-sensitive <it>S</it>. <it>aureus</it>'s (MSSA) were misidentified as MRSA's. The double-locus detection assay misidentified 55 out of 90 MSSA's. 46 MSSA containing samples were misidentified as MRSA and 9 as other than <it>S. aureus </it>ending with low positive predicted value (<85%) and very low specificity (<62%).</p> <p>Conclusion</p> <p>The results indicate that high prevalence of false-positive and false-negative reactions occurs in such assays.</p

Mitochondrial echoes of first settlement and genetic continuity in El Salvador

Background: From Paleo-Indian times to recent historical episodes, the Mesoamerican isthmus played an important role in the distribution and patterns of variability all around the double American continent. However, the amount of genetic information currently available on Central American continental populations is very scarce. In order to shed light on the role of Mesoamerica in the peopling of the New World, the present study focuses on the analysis of the mtDNA variation in a population sample from El Salvador. Methodology/Principal Findings: We have carried out DNA sequencing of the entire control region of the mitochondrial DNA (mtDNA) genome in 90 individuals from El Salvador. We have also compiled more than 3,985 control region profiles from the public domain and the literature in order to carry out inter-population comparisons. The results reveal a predominant Native American component in this region: by far, the most prevalent mtDNA haplogroup in this country (at ~90%) is A2, in contrast with other North, Meso- and South American populations. Haplogroup A2 shows a star-like phylogeny and is very diverse with a substantial proportion of mtDNAs (45%; sequence range 16090–16365) still unobserved in other American populations. Two different Bayesian approaches used to estimate admixture proportions in El Salvador shows that the majority of the mtDNAs observed come from North America. A preliminary founder analysis indicates that the settlement of El Salvador occurred about 13,400±5,200 Y.B.P.. The founder age of A2 in El Salvador is close to the overall age of A2 in America, which suggests that the colonization of this region occurred within a few thousand years of the initial expansion into the Americas. Conclusions/Significance: As a whole, the results are compatible with the hypothesis that today's A2 variability in El Salvador represents to a large extent the indigenous component of the region. Concordant with this hypothesis is also the observation of a very limited contribution from European and African women (~5%). This implies that the Atlantic slave trade had a very small demographic impact in El Salvador in contrast to its transformation of the gene pool in neighbouring populations from the Caribbean facade

A taxonomy of multinational ethical and methodological standards for clinical trials of therapeutic interventions

BACKGROUND: If trials of therapeutic interventions are to serve society’s interests, they must be of high methodological quality and must satisfy moral commitments to human subjects. The authors set out to develop a clinical-trials compendium in which standards for the ethical treatment of human subjects are integrated with standards for research methods. METHODS: The authors rank-ordered the world’s nations and chose the 31 with >700 active trials as of 24 July 2008. Governmental and other authoritative entities of the 31 countries were searched, and 1004 English-language documents containing ethical and/or methodological standards for clinical trials were identified. The authors extracted standards from 144 of those: 50 designated as ‘core’, 39 addressing trials of invasive procedures and a 5% sample (N=55) of the remainder. As the integrating framework for the standards we developed a coherent taxonomy encompassing all elements of a trial’s stages. FINDINGS: Review of the 144 documents yielded nearly 15 000 discrete standards. After duplicates were removed, 5903 substantive standards remained, distributed in the taxonomy as follows: initiation, 1401 standards, 8 divisions; design, 1869 standards, 16 divisions; conduct, 1473 standards, 8 divisions; analysing and reporting results, 997 standards, four divisions; and post-trial standards, 168 standards, 5 divisions. CONCLUSIONS: The overwhelming number of source documents and standards uncovered in this study was not anticipated beforehand and confirms the extraordinary complexity of the clinical trials enterprise. This taxonomy of multinational ethical and methodological standards may help trialists and overseers improve the quality of clinical trials, particularly given the globalisation of clinical research

A Subset of Replication Proteins Enhances Origin Recognition and Lytic Replication by the Epstein-Barr Virus ZEBRA Protein

ZEBRA is a site-specific DNA binding protein that functions as a transcriptional activator and as an origin binding protein. Both activities require that ZEBRA recognizes DNA motifs that are scattered along the viral genome. The mechanism by which ZEBRA discriminates between the origin of lytic replication and promoters of EBV early genes is not well understood. We explored the hypothesis that activation of replication requires stronger association between ZEBRA and DNA than does transcription. A ZEBRA mutant, Z(S173A), at a phosphorylation site and three point mutants in the DNA recognition domain of ZEBRA, namely Z(Y180E), Z(R187K) and Z(K188A), were similarly deficient at activating lytic DNA replication and expression of late gene expression but were competent to activate transcription of viral early lytic genes. These mutants all exhibited reduced capacity to interact with DNA as assessed by EMSA, ChIP and an in vivo biotinylated DNA pull-down assay. Over-expression of three virally encoded replication proteins, namely the primase (BSLF1), the single-stranded DNA-binding protein (BALF2) and the DNA polymerase processivity factor (BMRF1), partially rescued the replication defect in these mutants and enhanced ZEBRA's interaction with oriLyt. The findings demonstrate a functional role of replication proteins in stabilizing the association of ZEBRA with viral DNA. Enhanced binding of ZEBRA to oriLyt is crucial for lytic viral DNA replication